PDS Biotech says Phase 2 study shows 39.3-month median survival for PDS0101 plus pembrolizumab in HPV16-positive head and neck cancer
PDSB•Strategy and financing update
PDS Biotech said its strategy shifts toward prioritizing PDS0301 in metastatic colorectal cancer while pursuing a partnership for PDS0101.
Financing included an initial PIPE closing of up to USD 22.3 million, tied to a one-year exclusive license negotiation window for PDS0101.
Phase 2 VERSATILE-002 results published in JAMA Oncology
PDS Biotech published Phase 2 VERSATILE-002 results in JAMA Oncology for PDS0101 with pembrolizumab in HPV16-positive head and neck cancer.
Results were presented as a journal publication, not a future conference update.
The study showed stronger survival and response outcomes than published benchmarks for standard pembrolizumab, with a tolerable safety profile.
